Table 3. Association of change in eGFR with change in urinary AGT or increased urinary AGT.

Parameters	Model 1		Model 2		Model 3
	B (95% CI)/β	P	B (95% CI)/β	P	B (95% CI)/β	P
AGT/Cr*	−0.98 (−1.82, −0.15)/−0.24	0.022	−1.00 (−1.84, −0.16)/−0.25	0.020	−0.37 (−1.25, 0.51)/−0.09	0.401
ΔAGT*	−0.65 (−1.11, −0.19)/−0.29	0.006	−0.86 (−1.35, −0.38)/−0.38	0.001	−0.84 (−1.30, −0.37)/−0.37	0.001
i) Non-RAS blocker user	−0.92 (−1.42, −0.42)/−0.44	< 0.001	−0.97 (−1.48, −0.46)/−0.47	< 0.001	−0.86 (−1.36, −0.35)/−0.41	0.001
ii) RAS blocker user	−0.58 (−1.45, 0.29)/−0.24	0.184	−0.91 (−2.00, 0.18)/−0.37	0.098	−0.86 (−2.00, 0.28)/−0.35	0.131
Increased AGT, yes/no	−2.76 (−5.63, 0.12)/−0.20	0.060	−4.49 (−7.62, −1.36)/−0.32	0.006	−4.36 (−7.37, −1.35)/−0.31	0.005

Multivariate linear regression analysis. B means unstandardized coefficient and β means standardized coefficient. Model 1: crude; Model 2: adjusted for baseline age, SBP, HbA1c, TG^*, LDL cholesterol, HDL cholesterol, eGFR, AGT/Cr^*; Model 3: adjusted for ACR^* and use of lipid-lowering agent at baseline, use of RAS inhibitors during follow-up.

eGFR = estimated glomerular filtration rate, AGT = angiotensinogen, CI = confidence interval, Cr = creatinine, ΔAGT = changes in urinary levels of AGT, RAS = renin-angiotensin system, SBP = systolic blood pressure, HbA1c = hemoglobin A1c, TG = triglyceride, LDL = low-density lipoprotein, HDL = high-density lipoprotein, ACR = albumin-to-creatinine ratio.

^*ACR, AGT/Cr, ΔAGT, and TG were logarithm-transformed.